Tempus AI (NASDAQ:TEM) Stock Rating Reaffirmed as Buy by Needham & Company LLC

Posted by Brenda Bartman on Oct 23rd, 2026

Tempus AI (NASDAQ:TEM – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a report issued on Friday, Benzinga reports. They presently have a $75.00 price target on the stock. Needham & Company LLC‘s price objective would indicate a potential upside of 10.93% from the company’s previous close.

Several other equities analysts have also recently weighed in on TEM. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. The Goldman Sachs Group began coverage on Tempus AI in a research report on Monday, September 21st. They issued a “neutral” rating and a $75.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on Tempus AI from $45.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 14th. Canaccord Genuity Group raised their price objective on Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, October 12th. Finally, Guggenheim raised their price objective on Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Eleven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $72.37.

Get Our Latest Analysis on Tempus AI

Tempus AI Stock Up 6.0%

Shares of NASDAQ:TEM traded up $3.80 during midday trading on Friday, hitting $67.61. The stock had a trading volume of 4,678,111 shares, compared to its average volume of 6,190,961. Tempus AI has a 12 month low of $40.77 and a 12 month high of $93.38. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The business’s 50-day simple moving average is $68.93 and its 200-day simple moving average is $57.12. The company has a market cap of $12.20 billion, a P/E ratio of -46.95 and a beta of 3.54.

Tempus AI (NASDAQ:TEM – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same period last year, the business earned ($0.22) earnings per share. The firm’s revenue was up 21.6% on a year-over-year basis. On average, sell-side analysts forecast that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Insider Activity at Tempus AI

In related news, CEO Ryan Fukushima sold 41,095 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $2,038,722.95. Following the transaction, the chief executive officer directly owned 562,463 shares in the company, valued at approximately $27,903,789.43. This represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the completion of the transaction, the executive vice president owned 146,067 shares in the company, valued at $7,246,383.87. This trade represents a 13.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,280,965 shares of company stock valued at $80,397,564 in the last 90 days. Insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the business. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after acquiring an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. grew its stake in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares in the last quarter. Eagle Health Investments LP bought a new stake in shares of Tempus AI during the 1st quarter valued at $11,588,000. Washington Trust Advisors Inc. lifted its position in shares of Tempus AI by 35.7% during the 3rd quarter. Washington Trust Advisors Inc. now owns 121,039 shares of the company’s stock valued at $9,913,000 after acquiring an additional 31,873 shares during the period. Finally, Swiss National Bank lifted its position in shares of Tempus AI by 0.3% during the 1st quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after acquiring an additional 600 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

Positive Sentiment: Needham reiterates Buy rating: Needham & Company maintained its Buy recommendation and set a $75 price target, implying roughly 11% upside from the cited share price. The call reinforces Wall Street support for Tempus’ growth outlook. Needham analyst recommendations
Positive Sentiment: Expanded Bristol Myers Squibb relationship: Tempus announced multi-year oncology and AI-data agreements with Bristol Myers Squibb, a major pharmaceutical validation of its clinical-data platform. The collaboration could support recurring data-related revenue and increase Tempus’ role in drug development. Tempus expands Bristol Myers partnership
Positive Sentiment: New Pathos AI partnership expands neuroscience reach: Tempus is partnering with Pathos AI and Bristol Myers Squibb on medical research, including neurology and neuroscience applications. Pathos’ $237 million financing and approximately $3 billion valuation may increase the visibility and perceived strategic value of Tempus’ data and AI capabilities. Tempus expands neurology data partnership
Positive Sentiment: Investor commentary remains constructive: Recent analyses describe Tempus as less risky than previously viewed and highlight its proprietary healthcare-data advantage, as well as its involvement with Moderna’s cancer-vaccine efforts. These opinions add momentum, although they are not company financial results. Tempus AI less risky analysis
Neutral Sentiment: Tempus remains unprofitable and carries elevated volatility, so investors will likely focus on whether these partnerships translate into sustained revenue growth and improved margins. The company’s recent quarterly results showed stronger-than-expected revenue and a narrower-than-expected loss, but execution remains important.

About Tempus AI

(Get Free Report)

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.